Reductions in blood pressure and lipid parameters are generally lower than those previously projected , though substantial heterogeneity of results exists .
Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo , single drug active component , or usual care but may be associated with improved adherence to a multidrug regimen .
BACKGROUND Cardiovascular disease ( CVD ) is the leading cause of death and disability worldwide , yet CVD risk factor control and secondary prevention rates remain low .
A fixed-dose combination of blood pressure and cholesterol lowering and antiplatelet treatments into a single pill , or polypill , has been proposed as one strategy to reduce the global burden of CVD by up to 80 % given its potential for better adherence and lower costs .
OBJECTIVES To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood pressure and lipid CVD risk factors for both primary and secondary prevention of CVD .
We also aim ed to determine discontinuation rates , adverse events , health-related quality of life , and costs of fixed-dose combination therapy .
Impact of Combination Therapy with Amlodipine and Atorvastatin on Plasma Adiponectin Levels in Hypertensive Patients with Coronary Artery Disease: Combination Therapy and Adiponectin
Abstract Background : In many countries , combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia . The aim of this study was to investigate the impact of this combination therapy on plasma adiponectin levels . Hypothesis : Combination therapy with amlodipine and atorvastatin would increase plasma adiponectin levels . Methods : A total of 25 patients with coronary artery disease and concomitant hypertension and hypercholesterolemia were evaluated . The combination of amlodipine and atorvastatin in 8 different dosage strengths were flexibly titrated over a period of 14 weeks . Lipid profile and plasma adiponectin were measured . Brachial flow-mediated dilation ( FMD ) was determined by vascular ultrasound . Results : As compared with baseline , combination therapy with amlodipine and atorvastatin significantly reduced systolic and diastolic blood pressure , total cholesterol , and low-density lipoprotein cholesterol ( all P < 0.05 ) . Furthermore , there were significant increases in adiponectin levels ( mean [ 95 % confidence interval ( CI ) ] , 12.1 [ 10.7 - 13.7 ] vs 8.1 [ 6.5 - 10.0 ] μg/mL ; P < 0.001 ) and brachial FMD ( 4.4 ± 0.6 % vs 5.6 ± 0.5 % ; P = 0.046 ) over 14 weeks of treatment . The change in adiponectin levels correlated significantly with the changes in diastolic blood pressure ( r = −0.49 ; P = 0.014 ) and FMD ( r = 0.55 ; P = 0.007 ) . Conclusion : The results of this study indicate that along with its antihypertensive and cholesterol-lowering effects , combination therapy with amlodipine and atorvastatin appears to increase plasma adiponectin levels and improve endothelial function
Reductions in blood pressure and lipid parameters are generally lower than those previously projected , though substantial heterogeneity of results exists .
Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo , single drug active component , or usual care but may be associated with improved adherence to a multidrug regimen .
BACKGROUND Cardiovascular disease ( CVD ) is the leading cause of death and disability worldwide , yet CVD risk factor control and secondary prevention rates remain low .
A fixed-dose combination of blood pressure and cholesterol lowering and antiplatelet treatments into a single pill , or polypill , has been proposed as one strategy to reduce the global burden of CVD by up to 80 % given its potential for better adherence and lower costs .
OBJECTIVES To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood pressure and lipid CVD risk factors for both primary and secondary prevention of CVD .
We also aim ed to determine discontinuation rates , adverse events , health-related quality of life , and costs of fixed-dose combination therapy .